711014-71-0

Upstream product

• 58550-34-8 (E)-2-methyl-3-(4-nitrophenyl)acrylaldehyde 
• 867-13-0 diethoxyphosphoryl-acetic acid ethyl ester 
• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 

Downstream Products

• 838895-96-8 ethyl 5-(4-aminophenyl)-4-methylpentanoate 
• 711014-76-5 (2E,4E)-5-(4-(4-chlorobenzenesulfonylamino)phenyl)-4-methylpenta-2,4-dienoic acid ethyl ester 
• 838895-98-0 ethyl 5-[4-(4-chlorobenzenesulfonylamino)phenyl]-4-methylpentanoate 
• 711014-77-6 (2E,4E)-5-(4-(4-methoxybenzenesulfonylamino)phenyl)-4-methylpenta-2,4-dienoic acid ethyl ester 
• 711014-75-4 (2E,4E)-5-(4-benzenesulfonylaminophenyl)-4-methylpenta-2,4-dienoic acid ethyl ester 
• 711014-74-3 (2E,4E)-5-(4-aminophenyl)-4-methylpenta-2,4-dienoic acid ethyl ester 

Relevant academic research and scientific papers

SN2″-Selective and Enantioselective Substitution with Unsaturated Organoboron Compounds and Catalyzed by a Sulfonate-Containing NHC-Cu Complex

The first broadly applicable strategy for SN2″-selective and enantioselective catalytic substitution is disclosed. Transformations are promoted by 5.0 mol% of a sulfonate-containing NHC-Cu complex (NHC = N-heterocyclic carbene), and are carried

PHARMACEUTICAL AGENTS

Use of compounds of formula (I) in the manufacture of a medicament for use in treating a disorder mediated by histone deacetylase: wherein the symbol ---- represents a single bond or a double bond or the symbol ---- R6 and R8 togethe

Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides

Syntheses of (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides are described, some of which are potent inhibitors of histone deacetylase, a double bond conferring more than a 10-fold increase in potency compared with the triple bond analogue oxamflatin.